The new partnership will make data from more than 9 million anonymized veterans' medical records available for research.
The company has been working with the VA since 2013, when it it received a contract to provide sequencing and data analysis for enrollees in the Million Veteran Program.
Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
With NIH funds, organizations will build the 1 million volunteer cohort, while FDA's draft guidances will inform regulation of genetic tests critical for precision medicine.
The deal, which will help develop personalized cancer treatments for veterans, marks the latest in a series of personalized medicine alliances for IBM.
The work will support the Million Veteran Program, which aims to study the link between genes and disease using a research cohort veterans and active military.
Dozens of government agencies, academic institutions, and a various public and private sector organizations have now committed to driving the initiative forward.
If the regional precision medicine program is successful, the VA might expand it for veterans around the country.
Personal Genome Diagnostics will supply its CancerSelect targeted gene panel to test veterans with newly diagnosed lung cancer.
NEW YORK (GenomeWeb) – The US Department of Veterans Affairs has awarded Bina Technologies a $1 million contract to conduct genomic analyses as part of the VA's Million Veteran Program, Bina said today.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.